SCISPARC LTD (SPRC) Stock Price, Forecast & Analysis
USA - NASDAQ:SPRC - IL0010951403 - Common Stock
SPRC Key Statistics, Chart & Performance
The current stock price of SPRC is 2.4 USD. In the past month the price decreased by -37.17%. In the past year, price decreased by -49.59%.
SPRC Latest News, Press Relases and Analysis
SPRC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Related stock screener links
About SPRC
Company Profile
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Company Info
SCISPARC LTD
20 Raul Wallenberg Street, Tower A
TEL AVIV-YAFO IL
Employees: 3
Phone: 97236103100
SCISPARC LTD / SPRC FAQ
Can you describe the business of SCISPARC LTD?
SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Can you provide the latest stock price for SCISPARC LTD?
The current stock price of SPRC is 2.4 USD. The price decreased by -6.25% in the last trading session.
What is the dividend status of SCISPARC LTD?
SPRC does not pay a dividend.
How is the ChartMill rating for SCISPARC LTD?
SPRC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in SCISPARC LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SPRC.
What is the market capitalization of SPRC stock?
SCISPARC LTD (SPRC) has a market capitalization of 3.89M USD. This makes SPRC a Nano Cap stock.
What is the outstanding short interest for SCISPARC LTD?
The outstanding short interest for SCISPARC LTD (SPRC) is 5.2% of its float.
SPRC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SPRC. When comparing the yearly performance of all stocks, SPRC is a bad performer in the overall market: 95.58% of all stocks are doing better.
SPRC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SPRC. The financial health of SPRC is average, but there are quite some concerns on its profitability.
SPRC Financial Highlights
Over the last trailing twelve months SPRC reported a non-GAAP Earnings per Share(EPS) of -16.9. The EPS increased by 36.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.87% | ||
| ROE | -63.28% | ||
| Debt/Equity | 0 |